Important Updates to the NCCN Drugs & Biologics Compendium Non-Small Cell Lung Cancer

FORT WASHINGTON, Pa., September 10, 2008 — The National Comprehensive Cancer Network, (NCCN), announces important updates to the NCCN DrugsandBiologics Compendium Non-Small Cell Lung Cancer. The following changes relate to use in the treatment of Non-Small Cell Lung Cancer and are as follows: Cetuximab (Erbitux, Bristol-Myers Squibb/ImC lone Systems Incorporated) - First-line therapy for recurrence or metastasis in combination with vinorelbine and cisplatin for performance status 0-2 patients ...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news